Compare · ATLN vs RVTY
ATLN vs RVTY
Side-by-side comparison of Atlantic International Corp. (ATLN) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATLN and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $17.26B, about 235.9x ATLN ($73.2M).
- RVTY has been more active in the news (7 items in the past 4 weeks vs 3 for ATLN).
- RVTY has more recent analyst coverage (23 ratings vs 0 for ATLN).
- Company
- Atlantic International Corp.
- Revvity Inc.
- Price
- -
- -
- Market cap
- $73.2M
- $17.26B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 3
- 7
- Recent ratings
- 0
- 23
Latest ATLN
- SEC Form 424B7 filed by Atlantic International Corp.
- Circle8 Netherlands Secures $314 Million Four-Year Contract With DUO Groningen
- Circle8 Netherlands Signs $492 Million Four-Year Contract Across Three Dutch Government Bodies
- Circle8 Confirms Proposal for SThree plc, Advancing Global IT and Technology Strategy
- Circle8 Group Delivers Record $569.7 Million First-Half Revenue, Up 177%
- SEC Form 10-Q filed by Atlantic International Corp.
- Amendment: Atlantic International Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- SEC Form NT 10-Q filed by Atlantic International Corp.
- Atlantic International Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- SEC Form 424B7 filed by Atlantic International Corp.
Latest RVTY
- Revvity to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Revvity
- Revvity to Host Investor Day
- VP and CAO Gonzales Anita sold $13,060 worth of shares (84 units at $155.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Revvity to Hold Earnings Call on November 3, 2026
- Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
- Officer Krakowiak Maxwell sold $235,728 worth of shares (1,631 units at $144.53) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 14,781 units (SEC Form 4)
- Officer Vohra Tajinder S sold $1,032,650 worth of shares (7,330 units at $140.88) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,635 units (SEC Form 4)
- UBS resumed coverage on Revvity with a new price target
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery